Selpercatinib
Potent and selective RET kinase inhibitor / Selpercatinib is a potent (IC50 = 0.45 nM)1 and selective inhibitor of RET kinase.2 Clinically relevant for the treatment of RET-altered non-small cell lung cancer3 and certain thyroid cancers4.
Biochemicals & reagents
2152628-33-4
LOXO-292
1) Kooijman et al. (2022); Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020, Front. Oncol., 12 953013 2) Subbiah et al. (2018), Selective RET kinase inhibition for patients with RET-altered cancers; Ann. Oncol. 29 1869 3) Drilon et al. (2020); Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancer, N. Engl. J. Med., 383 813 4) Wirth et al. (2020); Efficacy of Selpercatinib in RET-Altered Thyroid Cancer, N. Engl. J. Med., 383 825
-20°C
TARGET: Kinase -- DISEASE AREA: Cancer